Data from almost 28,000 people living with obesity is sharpening a question that has hovered over the rise of weight-loss injections: why do some bodies shed kilos rapidly while others barely move the needle? A large-scale analysis now points to inherited differences in how individuals regulate appetite, store fat and process drugs, suggesting that DNA may be a missing variable in the current enthusiasm for anti-obesity medicines.

Researchers examining clinical records and biobank samples linked patterns of response to common weight-loss injections, including GLP-1 receptor agonists, with specific gene variants. Some of these variants appear to influence receptors in the hypothalamus that govern satiety signals, while others alter hepatic enzymes that handle drug metabolism and clearance. The work overlaps with concepts familiar from pharmacogenomics in oncology, raising the prospect that obesity care could move beyond a one-size-fits-all protocol toward tailored dosing, drug choice and adjunct lifestyle advice calibrated to each patient’s genetic profile and baseline metabolic rate.

The emerging picture is less of a miracle cure and more of a complex system in which environment, behaviour and genome interact, with diminishing marginal effects from drugs when genetic and social constraints are strong. For clinicians and health systems, the findings hint at both an ethical and economic tension: precision prescribing could reduce wasted treatments and side effects, yet it also risks deepening disparities if access to genetic testing and specialist care remains uneven.